The Conversation (0)
Aion Therapeutic’s Dr. Stephen D. Barnhill to Present at Microdose “Psychedelic Capital Series” on September 3, 2020
Sep. 01, 2020 11:54AM PST
Psychedelics Investing
Aion Therapeutic Inc. (CSE:AION) (“Aion” or the “Company”) is pleased to announce that Dr. Stephen D. Barnhill, Executive Chair of the Board, will present live during the Microdose “Psychedelic Capital Series” on Thursday, September 3, 2020 at 1:15 P.M. Eastern Time.
Aion Therapeutic Inc. (CSE:AION) (“Aion” or the “Company”) is pleased to announce that Dr. Stephen D. Barnhill, Executive Chair of the Board, will present live during the Microdose “Psychedelic Capital Series” on Thursday, September 3, 2020 at 1:15 P.M. Eastern Time.
The Psychedelic Capital Series is an investor conference series diving deep into psychedelic medicine investment. Each month, Microdose presents a curated group of CEOs, capital advisors, and investment luminaries from around the world. Each session features two tracks. The first looks at the bigger picture, helping investors understand the psychedelic landscape. The second is a chance to hear from the hottest companies directly, in conversation with invited experts.
Presentations will be made between 1:00 and 4:00 P.M. Eastern Time on September 3, 2020. Tickets to the event are available at the following link:
Dr. Barnhill will address the conference at 1:15 P.M. Eastern Time on Thursday, September 3, 2020.
“Aion Therapeutic is pleased to sponsor this industry leading event and I am honored to present at this assemblage of investors and professionals looking to identify and discuss better opportunities in the psychedelic industry,” stated Dr. Barnhill. “Aion is actively developing and patent protecting novel therapeutic formulations using unique combinations of medical cannabis with psychedelic mushrooms (psilocybin), fungi (edible mushrooms) and other psychedelic and natural therapies to benefit patients with many types of illnesses including cancer, psychiatric disorders, addiction (opioid and alcohol), viral infections, obesity, chronic inflammation and more.”
“And I appreciate the opportunity to explain how we are leveraging the tremendous power of Artificial Intelligence (AI) to drive our personalized medicine discovery creating effective natural treatment formulations for use in our pharmaceutical, nutraceutical and cosmeceutical product lines,” Barnhill added.
About Aion Therapeutic Inc.
Aion Therapeutic Inc. (formerly, Osoyoos Cannabis Inc.) has a joint-venture agreement with a private, vertically-integrated licensed producer under the Cannabis Act (Canada) to offer contract tolling extraction services to third-party businesses. Additionally, the Company recently acquired 1196691 B.C. Ltd. d/b/a “PCAI Pharma” (www.pcai.ca) and its wholly-owned subsidiary AI Pharmaceuticals Jamaica Limited, a private corporation incorporated and operating under the laws of Jamaica. The business of AI Pharma involves, research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), and other psychedelic formulations. In addition, the Company is creating a strong international intellectual property portfolio related to their discoveries.
For further information, please contact:
Investor Relations & Financial Media
Integrity Media Inc.
team@integritymedia.com
Toll Free: (888) 216-3595
www.IntegrityMedia.com
Aion Therapeutic Inc.
Graham Simmonds
Executive Vice Chair & CEO
(416) 843-2881
DISCLAIMER & READER ADVISORY
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “may”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include regulatory and other third-party approvals; licensing and other risks. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
info
